To assess the impact of the intestinal microbiota on protection of mice with severely compromised adaptive immunity from bacterial translocation, we challenged GF- or SPF-raised Rag1 โˆ’/โˆ’ mice orally with E. coli strain Nissle 1917, a probiotic E. coli strain used to treat IBD and other intestinal diseases , or with E. coli mpk, a commensal Escherichia coli Nissle 1917 (Mutaflor) is one of the most extensively studied probiotic bacterium. It was isolated in 1917 by Prof. Nissle from feces from a soldier during the First World War, who did not suffer from diarrhoea as his comrades did. Prof. Nissle realized the potential health benefits early on [ 16 ].
Escherichia coli Nissle 1917 (EcN) is the active component of Muta๏ฌ‚orยฎ (Ardeypharm GmbH, Herdecke, Germany), a pro- biotic drug licensed in several countries for the treatment of
To this end, we chose Escherichia coli Nissle 1917 , a probiotic strain that is used commercially as a probiotic and is closely related to model strains of E. coli that are well characterized for
Boudeau, J., Glasser, A. L., Julien, S., Colombel, J. F. & Darfeuille-Michaud, A .Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal
Here we report that E. coli strain Nissle 1917 and a variety of other probiotic bacteria, including lactobacilli--in contrast to more than 40 different E. coli strains tested--strongly induce the expression of the antimicrobial peptide human beta-defensin-2 (hBD-2) in Caco-2 intestinal epithelial cells in a time- and dose-dependent manner. VkfdrX. 88 411 54 466 51 364 223 434 381

escherichia coli nissle 1917 probiotic